ANEB Company Profile and Key Details

Anebulo Pharmaceuticals, Inc. has 40.78 million shares outstanding. The public float is 3.40 million shares, elevated short interest at 0.76% of float. This equals 50.69 thousand shares. The short ratio is 0.81 days. Institutional investors hold 90.95% of the float. Insiders own 40.54%.

Anebulo Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.34. This means the shares are trading above this model’s fair value.

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) closed at $0.47 USD, losing -$0.01 (-2.13%) from the previous close of $0.48. The stock is currently mid-range between its 52-week high and low $0.43 and $3.42. With a market capitalization of about $19.29 million, Anebulo Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.81). Key stats such as the average daily volume over the past year has been around 87.46 thousand shares, in line with its 52-week average. Headquartered in Lakeway, TX, Anebulo Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard Anthony Cunningham, the company employs approximately 2 people and listed since May 07, 2021. Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction.

Anebulo Pharmaceuticals, Inc. trades at a P/E ratio of -2.44, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.45 suggesting the stock is closer to book value. The P/FCF stands at -3.3, also above market averages.

Our AI price prediction model suggests that Anebulo Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -51.37%, with price expected at $0.23 by March 06, 2026, within a range of $0.07 to $0.39 3-Month Outlook: Projected fall of -85.2%, reaching $0.07 by May 21, 2026, with a range of $0.00 to $0.14. 1-Year Outlook: Projected gain of 221.35%, with price at $1.52 by February 19, 2027, within a range of $0.00 to $1.73.

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) shares are flat 7.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Anebulo Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -2.44. Analyst sentiment is cautious, with the majority of ratings in Speculative Buy territory and a mean price target of $7.25, suggesting 1432.77% upside. Our AI forecast model points to short-term weakness (-51.37% over two weeks), a medium-term fall (-85.2% over three months), and a longer-term gain (221.35% over one year), with expected trading ranges indicating moderate volatility.